AdAlta Ltd.

AdCella will focus on identifying partners with the capability to develop multi-functional cellular immunotherapies. Credit: Lightspring/Shutterstock.com. Australian biotechnology company AdAlta has signed a memorandum of understanding (MOU) with SYNthesis BioVentures Fund (SYNBV) to explore the creation of a jointly owned special purpose entity, AdCella, for advanced cancer treatments. The collaboration will introduce cellular immunotherapies from Asia to Western markets, utilising AdAlta’s i-body technology. The partnership addresses the challenges of solid tumour treatments through enhanced cellular immunotherapies. The MOU expands AdAlta’s clinical stage pipeline in the field of cellular immunotherapy. AdCella will identify partners with the capability to develop multi-functional cellular immunotherapies for solid cancers. See Also: Medicxi and Starpharma to develop dendrimer-based cancer treatments AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer The MOU outlines a six-month collaboration period, extendable by a further six months, during which AdAlta and SYNBV will conduct due diligence and negotiate final agreements for asset selection. Upon successful asset acquisition, AdAlta will hold a 75% ownership of AdCella, with SYNBV holding the remaining 25% before the next financing round. SYNBV managing director Professor Andrew Wilks stated: “We believe that this collaboration will further our fund’s strategy of investing in promising early-stage science by leveraging the inherent advantages of the Australian biotech ecosystem.” AdCella’s goal is to license or acquire global commercialisation rights of the developed products outside Asia in return for carrying out clinical trials in Australia and integrating AdAlta’s i-body technology into its future product pipeline. AdAlta CEO and managing director Tim Oldham stated: “As part of our stated strategy to expand our clinical-stage pipeline with assets that work with our i-body platform, we have identified a unique and exciting opportunity to bring highly innovative cellular immunotherapies to Australian patients.” The partnership offers partner companies an opportunity to access Australia’s clinical and manufacturing ecosystem, AdAlta’s clinical trial capabilities and the i-body platform. Last month, AdAlta announced results from its Phase I extension study of lead asset AD-214, which is being developed for fibrotic diseases including the debilitating and fatal disease, idiopathic pulmonary fibrosis.

Medicxi’s investment in Petalion will be distributed in tranches. Credit: Alex_Traksel/Shutterstock.com. Life sciences investment company Medicxi has partnered with Starpharma for the formation of Petalion Therapeutics to develop dendrimer-based oncology treatments. The collaboration leverages Starpharma’s DEP dendrimer platform technology. Medicxi is committing $25m for the development of a new drug candidate. To be operated from the UK, the new company will initially focus on creating targeted dendrimer-drug conjugate therapies. Starpharma’s contribution to the partnership includes licensing its intellectual property to Petalion in exchange for a 22.5% stake in the new company. Starpharma will grant Petalion an exclusive licence for a specific target, receiving ordinary shares in return. See Also: AdAlta and SYNthesis to form AdCella for advanced cancer treatments AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer Starpharma will offer research and development services on a fee-for-service basis. Medicxi’s investment in Petalion will be distributed in tranches, contingent on achieving scientific and technical milestones. Starpharma CEO Cheryl Maley stated: “We are excited to announce this strategic partnership, which combines Starpharma’s expertise in developing dendrimer technology with Medicxi’s success in converting development candidates into high-value commercial assets. “If successful, the oncology therapies that Petalion will develop have the potential to become an important treatment modality for a potentially wide range of cancer indications. “This is just one of many ongoing efforts to prioritise the commercialisation of Starpharma’s DEP [diethyl phthalate] platform and our partnerships to advance the application of the DEP technology in high-value novel therapeutic areas.” Dr Mehdi Shahidi, who has an extensive background in pharmaceutical drug development, has been appointed as Petalion’s CEO. Shahidi stated: “Leveraging Starpharma’s world-leading technology and the scientific domain expertise from Medicxi’s asset-centric investment platform, our team at Petalion aims to develop best-in-class dendrimer conjugates with differentiated properties. “Our ultimate goal is to cultivate a targeted dendrimer-based drug that can effectively address unmet needs in cancer.” Medicxi’s portfolio company Versanis Bio. agreed to be acquired by Eli Lilly and Company last year.

DUBLIN, July 27, 2023 /PRNewswire/ -- The "Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering. The idiopathic pulmonary fibrosis (IPF) diagnostic and treatment market has shown promising growth, with a value of US$4.035 billion in 2021 and a projected CAGR of 12.58% from 2023 to 2028, reaching US$9.249 billion. This research study provides valuable insights into the market's key segments and geographic regions, outlining the driving factors, challenges, and competitive landscape. Market Dynamics: The market's growth is fueled by factors such as increasing awareness about IPF, advancements in diagnostic technologies, and a rising global burden of pulmonary fibrosis. However, the market is not without challenges, as regulatory policies and a competitive landscape influence the overall environment. Segmentation: The market is segmented based on the type of diagnostic and treatment solutions: Diagnostic Testing Pharmacological Drugs Surgical Treatment Geographic Coverage: The market analysis covers the following regions and key countries within them: North America (United States, Canada, Mexico) South America (Brazil, Argentina, and Others) Europe (United Kingdom, Germany, France, Spain, and Others) The Middle East and Africa (Saudi Arabia, UAE, Israel, and Others) Asia Pacific (Japan, China, India, South Korea, Indonesia, Thailand, and Others) Research Methodology: The study employs a robust research methodology to gather and analyze data, ensuring accuracy and relevance. Competitive Landscape: The report evaluates key market players and their strategies, categorizing them into four quadrants: leaders, followers, challengers, and niche players. It includes major players like: Roche Holding AG Boehringer Ingelheim AdAlta ATS Journals Mayo Clinic Medscape Conclusion: The idiopathic pulmonary fibrosis diagnostic and treatment market shows tremendous potential for growth in the coming years, driven by increasing awareness and advancements in diagnostic and treatment options. The market's competitive landscape presents opportunities for key players to capitalize on growth prospects and develop innovative solutions to address the rising burden of IPF globally. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets